Source | Evidence on protein | Close homologs |
---|---|---|
Cuervo et al. | no | yes: 0 |
Hassani et al. | no | yes: 0 |
Forrest at al. (metacyclic) | no | yes: 0 |
Forrest at al. (procyclic) | no | yes: 0 |
Silverman et al. | no | yes: 0 |
Pissara et al. | no | yes: 0 |
Source | Evidence on protein | Close homologs |
---|---|---|
Pires et al. | no | yes: 0 |
Source | Evidence on protein | Close homologs |
---|---|---|
Silverman et al. | no | yes: 0 |
Source | Evidence on protein | Close homologs |
---|---|---|
Jamdhade et al. | no | yes: 0 |
Source | Evidence on protein | Close homologs |
---|---|---|
DeepLoc | ||
SignalP6 | no | yes: 0, no: 6 |
NetGPI | no | yes: 0, no: 6 |
Term | Name | Level | Count |
---|---|---|---|
GO:0016020 | membrane | 2 | 1 |
GO:0110165 | cellular anatomical entity | 1 | 1 |
Related structures:
AlphaFold database: Q4Q3C9
Leishmania | From | To | Domain/Motif | Score |
---|---|---|---|---|
CLV_C14_Caspase3-7 | 53 | 57 | PF00656 | 0.681 |
CLV_NRD_NRD_1 | 209 | 211 | PF00675 | 0.700 |
CLV_NRD_NRD_1 | 7 | 9 | PF00675 | 0.537 |
CLV_PCSK_KEX2_1 | 111 | 113 | PF00082 | 0.491 |
CLV_PCSK_KEX2_1 | 209 | 211 | PF00082 | 0.692 |
CLV_PCSK_KEX2_1 | 7 | 9 | PF00082 | 0.538 |
CLV_PCSK_PC1ET2_1 | 111 | 113 | PF00082 | 0.476 |
DOC_ANK_TNKS_1 | 51 | 58 | PF00023 | 0.758 |
DOC_USP7_MATH_1 | 125 | 129 | PF00917 | 0.773 |
LIG_14-3-3_CanoR_1 | 112 | 120 | PF00244 | 0.681 |
LIG_14-3-3_CanoR_1 | 155 | 162 | PF00244 | 0.639 |
LIG_14-3-3_CanoR_1 | 34 | 42 | PF00244 | 0.668 |
LIG_BIR_II_1 | 1 | 5 | PF00653 | 0.720 |
LIG_FHA_1 | 71 | 77 | PF00498 | 0.664 |
LIG_FHA_2 | 165 | 171 | PF00498 | 0.755 |
LIG_FHA_2 | 51 | 57 | PF00498 | 0.816 |
LIG_LIR_Gen_1 | 170 | 180 | PF02991 | 0.619 |
LIG_LIR_Gen_1 | 25 | 31 | PF02991 | 0.812 |
LIG_LIR_Nem_3 | 170 | 175 | PF02991 | 0.733 |
LIG_LIR_Nem_3 | 25 | 30 | PF02991 | 0.812 |
LIG_NRP_CendR_1 | 209 | 212 | PF00754 | 0.787 |
LIG_Pex14_1 | 179 | 183 | PF04695 | 0.411 |
LIG_Pex14_2 | 175 | 179 | PF04695 | 0.411 |
LIG_Pex14_2 | 183 | 187 | PF04695 | 0.411 |
LIG_SH2_STAP1 | 12 | 16 | PF00017 | 0.751 |
LIG_SH2_STAP1 | 121 | 125 | PF00017 | 0.661 |
LIG_SH2_STAP1 | 185 | 189 | PF00017 | 0.513 |
LIG_SH2_STAT5 | 121 | 124 | PF00017 | 0.625 |
LIG_SH2_STAT5 | 182 | 185 | PF00017 | 0.524 |
LIG_SH2_STAT5 | 206 | 209 | PF00017 | 0.587 |
MOD_CK1_1 | 139 | 145 | PF00069 | 0.710 |
MOD_CK1_1 | 2 | 8 | PF00069 | 0.639 |
MOD_CK1_1 | 40 | 46 | PF00069 | 0.789 |
MOD_CK1_1 | 50 | 56 | PF00069 | 0.707 |
MOD_CK2_1 | 147 | 153 | PF00069 | 0.711 |
MOD_CK2_1 | 164 | 170 | PF00069 | 0.699 |
MOD_CK2_1 | 68 | 74 | PF00069 | 0.563 |
MOD_CK2_1 | 90 | 96 | PF00069 | 0.674 |
MOD_GlcNHglycan | 187 | 190 | PF01048 | 0.506 |
MOD_GlcNHglycan | 56 | 60 | PF01048 | 0.548 |
MOD_GSK3_1 | 33 | 40 | PF00069 | 0.764 |
MOD_GSK3_1 | 42 | 49 | PF00069 | 0.748 |
MOD_GSK3_1 | 68 | 75 | PF00069 | 0.593 |
MOD_N-GLC_1 | 38 | 43 | PF02516 | 0.575 |
MOD_NEK2_1 | 187 | 192 | PF00069 | 0.513 |
MOD_NEK2_1 | 195 | 200 | PF00069 | 0.486 |
MOD_NEK2_1 | 3 | 8 | PF00069 | 0.725 |
MOD_NEK2_1 | 42 | 47 | PF00069 | 0.718 |
MOD_NEK2_1 | 72 | 77 | PF00069 | 0.671 |
MOD_NEK2_2 | 119 | 124 | PF00069 | 0.688 |
MOD_PIKK_1 | 111 | 117 | PF00454 | 0.741 |
MOD_PIKK_1 | 154 | 160 | PF00454 | 0.633 |
MOD_PKA_1 | 111 | 117 | PF00069 | 0.686 |
MOD_PKA_2 | 111 | 117 | PF00069 | 0.669 |
MOD_PKA_2 | 154 | 160 | PF00069 | 0.745 |
MOD_PKA_2 | 33 | 39 | PF00069 | 0.696 |
MOD_PKB_1 | 32 | 40 | PF00069 | 0.667 |
MOD_Plk_1 | 38 | 44 | PF00069 | 0.755 |
MOD_Plk_2-3 | 90 | 96 | PF00069 | 0.691 |
MOD_SUMO_rev_2 | 130 | 140 | PF00179 | 0.744 |
TRG_DiLeu_BaEn_4 | 132 | 138 | PF01217 | 0.804 |
TRG_ENDOCYTIC_2 | 177 | 180 | PF00928 | 0.513 |
TRG_ER_diArg_1 | 209 | 212 | PF00400 | 0.513 |
TRG_ER_diArg_1 | 7 | 9 | PF00400 | 0.740 |
TRG_NES_CRM1_1 | 62 | 74 | PF08389 | 0.660 |
Protein | Taxonomy | Sequence identity | Coverage |
---|---|---|---|
A0A0N1PBG5 | Leptomonas seymouri | 42% | 89% |
A0A3S7X7I7 | Leishmania donovani | 91% | 100% |
A4HAI6 | Leishmania braziliensis | 64% | 98% |
E9AHS7 | Leishmania infantum | 91% | 100% |
E9B4P7 | Leishmania mexicana (strain MHOM/GT/2001/U1103) | 87% | 100% |